Hand holding the newspaper resting on a table with a cup of coffee

Newsroom

Taxonomy Icon
Ivy Brain Tumor Center Welcomes Biostatistician to Phase 0 Clinical Trials Program
  • September 29, 2020
The Ivy Brain Tumor Center at Barrow Neurological Institute is pleased to announce the addition of Wonsuk Yoo, PhD, as associate professor of biostatistics. Dr. Yoo’s expertise in preclinical and clinical trial design will be critical in evaluating new treatment modalities for brain tumor patients.
Taxonomy Icon
Ivy Brain Tumor Center Appoints Shwetal Mehta, Ph.D., as Chief Operating Officer
  • September 2, 2020
The Ivy Center has appointed Shwetal Mehta, Ph.D., as its chief operating officer. Dr. Mehta is a nationally recognized molecular neuro-oncologist who has distinguished herself as a rising star in brain tumor biology. 
Taxonomy Icon
Ivy Brain Tumor Center and Vivace Therapeutics Collaborate to Test Targeted Agent in Glioblastoma and Meningioma
  • August 26, 2020
Ivy Brain Tumor Center has announced a new partnership with Vivace Therapeutics. This collaboration will allow researchers at the Ivy Center to evaluate a first-in-class TEAD inhibitor in glioblastoma and meningioma.
Taxonomy Icon
Ivy Brain Tumor Center and BridgeBio Pharma’s QED Therapeutics announce dosing of first patient in investigator-initiated Phase 0/2 clinical trial of infigratinib in recurrent glioblastoma
  • July 28, 2020
The Ivy Brain Tumor Center announced that the first patient has been dosed in an investigator-initiated Phase 0/2 clinical trial of infigratinib in recurrent high-grade glioma driven by FGFR genetic alterations. Infigratinib is an investigational, orally administered, FGFR1-3 selective tyrosine kinase inhibitor being developed by BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate company QED Therapeutics, Inc.
Taxonomy Icon
Phoenix nurse inspires hope during battle with brain cancer
  • July 22, 2020
  • Source: 12 News
Dr. Nader Sanai, director of the Ivy Brain Tumor Center, says although the survival rate is low it doesn't mean there isn't hope to beat cancer. "These are populational statistics, they don't describe you or predict your future." He and Youngblood are teaming up to bring awareness to the disease for Glioblastoma Awareness Day. Sanai says a day focusing on brain cancer is important because it hasn't seen the same progress in therapies like breast or prostate cancer.
Taxonomy Icon
Arizona is Leading the Charge in Battling one of the ‘Deadliest Diseases Known to Mankind’
  • July 21, 2020
  • Source: Chamber Business News
Chamber Business News highlights the Ivy Brain Tumor Center's resilience in fighting brain tumors despite the pandemic and the importance of Glioblastoma Awareness Day. Observed as a day to honor those who have been impacted by the disease, the initiative also supports efforts to develop better treatment options that will improve patients’ long-term prognosis.
Taxonomy Icon
Phoenix nurse who helped fight New York’s COVID-19 surge now battling brain cancer
  • July 20, 2020
  • Source: azcentral
The Arizona Republic shares the story of Ian Youngblood, a 29-year-old nurse from Arizona who received a harrowing diagnosis of glioblastoma while helping fight COVID-19 on the frontlines in NYC. Dr. Nader Sanai weighs in on why these types of tumors are so hard to control and what it will take to move the needle on identifying new, effective treatment options.
Taxonomy Icon
Ivy Brain Tumor Center and COVID Nurse, Ian Youngblood, Honor Second Annual National Glioblastoma Day on July 22, 2020
  • July 17, 2020
Dr. Nader Sanai, director of the Ivy Brain Tumor Center and Ian Youngblood, RN, who was recently diagnosed with a brain tumor, have come together for the second annual Glioblastoma Awareness Day (#GBMDay) on July 22, 2020 to raise national consciousness.
Taxonomy Icon
Nurse who fought coronavirus in New York now battles his own brain cancer
  • July 10, 2020
  • Source: TODAY Show
Ian's story has moved the country for his strength and selfless service on the COVID-19 frontlines in NYC. Now, facing a battle of his own, he's turning to Dr. Nader Sanai and his team at the Ivy Brain Tumor Center and Barrow Neurological Institute to help him fight one of the most aggressive forms of brain cancer, glioblastoma.
Taxonomy Icon
Benjamin Cravatt, Ph.D. Joins Ivy Brain Tumor Center’s Scientific Advisory Board
  • June 24, 2020
The Ivy Brain Tumor Center at Barrow Neurological Institute has announced the appointment of Benjamin Cravatt, Ph.D to its Scientific Advisory Board. Dr. Cravatt is a world-renowned chemical biologist with extensive experience in drug discovery and drug development.